Pregnancy and Temporary Interruption of Endocrine Therapy May Be Safe in Adjuvant HR+ Breast Cancer – MASCC

The Multinational Association of Supportive Care in Cancer (MASCC) shared on LinkedIn:

“In this Supportive Care Digest, Dr. Mélanie Janson provides an overview of the POSITIVE study (Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine-Responsive Breast Cancer).

Take home message: Pregnancy and temporary interruption of endocrine therapy appears to be safe and may be considere during the adjuvant phase of HR+ breast cancer.”

Title: Updated results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial

Authors: O. Pagani, S.M. Niman, M. Ruggeri, F.A. Peccatori, H.A. Azim Jr, M. Colleoni, C. Saura, C. Shimizu, A.B. Sætersdal, J.R. Kroep, E. Warner, F. Amant, A. Mailliez, H.C.F. Moore, M. Ruiz-Borrego, J.M. Walshe, V.F. Borges, A. Gombos, A. Kataoka, C. Rousset-Jablonski, S. Borstnar, J. Takei, J.E. Lee, C. Saunders, V. Bjelic-Radisic, S. Susnjar, F. Cardoso, N.J. Klar, T. Ferreiro, K. Ribi, K.J. Ruddy, R. Kammler, S. El-Abed, G. Viale, M. Piccart, L.A. Korde, A. Goldhirsch, R.D. Gelber, A.H. Partridge

Read the article 

Other articles about Breast Cancer on OncoDaily.